Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) Director J. Scott Garland sold 13,000 shares of the firm’s stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $46.67, for a total value of $606,710.00. Following the completion of the transaction, the director directly owned 13,000 shares of the company’s stock, valued at $606,710. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Enliven Therapeutics Stock Down 3.2%
Shares of NASDAQ:ELVN traded down $1.50 during midday trading on Monday, reaching $45.47. 821,495 shares of the company traded hands, compared to its average volume of 1,258,190. Enliven Therapeutics, Inc. has a 12 month low of $14.78 and a 12 month high of $62.32. The firm has a market capitalization of $3.33 billion, a price-to-earnings ratio of -27.23 and a beta of 0.24. The firm’s fifty day moving average price is $55.23 and its two-hundred day moving average price is $47.39.
Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.10). Analysts forecast that Enliven Therapeutics, Inc. will post -1.75 earnings per share for the current year.
Analyst Ratings Changes
View Our Latest Report on Enliven Therapeutics
Institutional Investors Weigh In On Enliven Therapeutics
Institutional investors and hedge funds have recently bought and sold shares of the stock. First Light Asset Management LLC lifted its position in Enliven Therapeutics by 574.1% during the second quarter. First Light Asset Management LLC now owns 1,360,750 shares of the company’s stock valued at $69,058,000 after purchasing an additional 1,158,883 shares during the last quarter. Tidal Investments LLC raised its position in shares of Enliven Therapeutics by 27.7% during the 2nd quarter. Tidal Investments LLC now owns 60,694 shares of the company’s stock valued at $3,080,000 after buying an additional 13,179 shares in the last quarter. WINTON GROUP Ltd bought a new stake in shares of Enliven Therapeutics during the 2nd quarter worth $228,000. Engineers Gate Manager LP purchased a new position in Enliven Therapeutics in the second quarter worth $1,479,000. Finally, Squarepoint Ops LLC bought a new position in Enliven Therapeutics in the second quarter valued at $259,000. 95.08% of the stock is owned by hedge funds and other institutional investors.
About Enliven Therapeutics
Enliven Therapeutics, Inc (NASDAQ: ELVN) is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for the treatment of cancer. The company seeks to develop therapies designed to address significant unmet needs in oncology, with an emphasis on targeted treatments that may offer improved efficacy, safety, or durability.
Enliven’s pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for patients with chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for the treatment of HER2-driven cancers.
Read More
- Five stocks we like better than Enliven Therapeutics
- NVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can Run
- A Manufacturing Surprise Could Be a Big Win for These 2 Companies
- What a $1 Billion Chip Deal Says About Amazon’s AI Ambitions
- 3 Stocks Benefiting From AI Demand Just Announced Major Buybacks
Receive News & Ratings for Enliven Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enliven Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
